Skip to Main content Skip to Navigation
Theses

Stratégies de prise en charge de la polyarthrite rhumatoïde : quelle place pour les médicaments biosimilaires ?

Abstract : Biological drugs are associated with high procurement costs and heavily impact the financial burden imposed by rheumatoid arthritis on society. The purpose of this work was to investigate the benefits of using biosimilar drugs in rheumatoid arthritis patients. This work showed the introduction of biosimilar infliximab could lead to substantial annual cost savings of up to €13.6 million nationally, to treat rheumatoid arthritis patients only. Moreover, a biosimilar survey involving rheumatologists and pharmacists allowed us to identify the main issues at stake. Finally, the monitoring of their use in Grand Est region between 2015 and 2016 account for their relatively low utilization rate. The regular launch of new biosimilar medicines, together with growing experience of healthcare players and incentive policies, should allow to increase biosimilar uptake in the future, and also to make sure they meet well their commitments in terms of savings generated.
Complete list of metadatas

https://tel.archives-ouvertes.fr/tel-01715097
Contributor : Abes Star :  Contact
Submitted on : Thursday, February 22, 2018 - 12:56:11 PM
Last modification on : Tuesday, March 17, 2020 - 11:38:02 AM
Long-term archiving on: : Wednesday, May 23, 2018 - 12:57:44 PM

File

BECK_Morgane_2017_ED414.pdf
Version validated by the jury (STAR)

Identifiers

  • HAL Id : tel-01715097, version 1

Collections

Citation

Morgane Beck. Stratégies de prise en charge de la polyarthrite rhumatoïde : quelle place pour les médicaments biosimilaires ?. Rhumatologie et système ostéo-articulaire. Université de Strasbourg, 2017. Français. ⟨NNT : 2017STRAJ039⟩. ⟨tel-01715097⟩

Share

Metrics

Record views

430

Files downloads

161